Daniel Whitmer, MD
Family Medicine · Beavercreek, OHNPI 1649377391
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,925 of the $6,863 with a category attached, or 71.8%. 21 manufacturers reported payments, led by Genentech, Inc. at 38.2% of the total. 2025 is the largest year on record at $3,281, 7.4 times the $443 reported in 2019. Among family medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $63.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- Johnson & Johnson$1K
- Novartis$631
- AbbVie$281
- Phathom Pharmaceuticals, Inc.$250
- GSK$229
- plus $2K from 15 others
Across 87 payments — averaging $3175.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$177K
- AstraZeneca$23K
- Bristol Myers Squibb$19K
- Sumitomo Pharma America, Inc.$17K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- F. Hoffmann-la Roche AG$14K
- plus $11K from 2 others
What the payments were for
- Travel & lodging$1,93928%
- Food & beverage$4,92572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 7 | $2,621 |
| Johnson & Johnson | 18 | $1,106 |
| Novartis | 34 | $631 |
| AbbVie(2 entities) | 6 | $281 |
| Phathom Pharmaceuticals, Inc. | 2 | $250 |
| GSK | 2 | $229 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $181 |
| Corcept Therapeutics | 6 | $175 |
| Lilly USA, LLC | 9 | $174 |
| AstraZeneca | 2 | $172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $159 |
| Sanofi-aventis U.S. LLC | 3 | $154 |
| Biohaven Pharmaceuticals, Inc. | 2 | $146 |
| Novo Nordisk | 2 | $143 |
| Esperion Therapeutics, Inc. | 2 | $139 |
| Biogen | 2 | $133 |
| Amgen | 1 | $71 |
| Medtronic | 1 | $45 |
| Boehringer Ingelheim | 2 | $27 |
| Astellas Pharma US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,863 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $60,352 |
| EliquisApixaban | 51 | $57,536 |
| JardianceEmpagliflozin | 46 | $48,955 |
| SpravatoEsketamine Hcl | 20 | $38,844 |
| MounjaroTirzepatide | 22 | $25,350 |
| MyrbetriqMirabegron | 33 | $23,022 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $21,204 |
| TrulicityDulaglutide | 12 | $20,795 |
| JanuviaSitagliptin Phosphate | 12 | $20,676 |
| XareltoRivaroxaban | 18 | $15,358 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,904 |
| Repatha SureclickEvolocumab | 11 | $8,275 |
| LinzessLinaclotide | 13 | $7,398 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $6,541 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $143 | $60,35245 claims |
| Johnson & JohnsonSpravato, Xarelto | $1,106 | $54,20238 claims |
| Boehringer IngelheimJardiance | $27 | $48,95546 claims |
| Lilly USA, LLCMounjaro, Trulicity | $174 | $46,14534 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $23,02233 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $229 | $14,03525 claims |
| AbbVieLinzess, Synthroid | $281 | $9,95170 claims |
| Sanofi-aventis U.S. LLCLantus | $154 | $1,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Beavercreek
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.